Treatment of Psoriasis with Interleukin-10

Reich, Kristian; Grafe, Andrea; Vente, Claudia; Neumann, Christine; Brück, Monika; Garbe, Claus

doi:10.1046/j.1523-1747.1998.00444.x

Cited by 58 publications

(38 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6). Similar clinical effectiveness of IL-10 application has recently been reported by Reich et al (1998). In this open-label phase II trial, ten patients were treated subcutaneously with 4 g/kg rhIL-10 daily.…”

Section: E Therapy Of Psoriasismentioning

confidence: 75%

See 1 more Smart Citation

Interleukin-10 Therapy—Review of a New Approach

2003

View full text Add to dashboard Cite

Section: E Therapy Of Psoriasismentioning

confidence: 75%

“…These patients are a subgroup of the study by Reich et al (2001). Reich et al, 1998 Phase II in exacerbated psoriasis vulgaris…”

Section: E Therapy Of Psoriasismentioning

confidence: 99%

Interleukin-10 Therapy—Review of a New Approach

2003

View full text Add to dashboard Cite

“…Although we did not detect an increase in IL-10 mRNA in posttreatment biopsies studied, it could be increased at earlier time points, as previously reported. 22,26,27,39 Increased IL-10 has been shown to decrease dendritic cell activation, decrease IL-12, and stimulate a type 2 T-cell response. 22,26,27,39 Recently, several biologic drugs that antagonize type 1 cytokines have entered clinical trials in dermatology.…”

Section: Commentmentioning

confidence: 99%

Narrowband (312-nm) UV-B Suppresses Interferon γ and Interleukin (IL) 12 and Increases IL-4 Transcripts

Walters

Ozawa²,

Cardinale³

et al. 2003

Arch Dermatol

View full text Add to dashboard Cite

show abstract

“…Psoriasis is a common, chronically relapsing, T cell-dependent disease characterized by a type-1 cytokine pattern with predominant expression of IL-2 and IFN-+ and the relative lack of IL-4 and IL-10 in skin lesions [14]. It was shown in several clinical studies [13,15,16] that IL-10 has positive clinical effects on skin lesions and causes a lasting Th1/Th2 shift in vivo [17].…”

Section: Introductionmentioning

confidence: 99%

Expression profiling of IL‐10‐regulated genes in human monocytes and peripheral blood mononuclear cells from psoriatic patients during IL‐10 therapy

et al. 2004

View full text Add to dashboard Cite

Interleukin‐10 (IL‐10), originally identified as an inhibitor of pro‐inflammatory cytokine production, exerts multiple immunomodulatory functions. Its ability to inhibit a Th1 response has been used in clinical trials for the treatment of inflammatory diseases including psoriasis. However, little is known about the molecular mechanisms of IL‐10 functions. We aimed at identifying possiblemediators of in vitro IL‐10 treatment in monocytes by gene chip technology using Hu95a Affymetrix mRNA arrays with 12,000 genes. To prove relevance of the identified genes for the clinicalsituation we compared these in vitro results with genes being regulated by IL‐10 in peripheral blood mononuclear cells from psoriatic patients undergoing IL‐10 therapy. A high proportion of the 1,600 genes up‐regulated and 1,300 genes down‐regulated in vitro was found to be similarly regulated in vivo. Some genes, which were previously unknown to be regulated by IL‐10, can be assigned to known IL‐10 functions like e.g. the increase of pathogen clearance. Other new potentially immunomodulating genes have been identified to be regulated by IL‐10, but their impact needs to be experimentally evaluated. We could confirm a recently reported up‐regulation of heme oxygenase‐1 (HO‐1). However, we demonstrate that the anti‐inflammatory mechanisms of IL‐10 remain functional even when HO‐1 is irreversibly inhibited.

show abstract

Treatment of Psoriasis with Interleukin-10

Cited by 58 publications

References 12 publications

Interleukin-10 Therapy—Review of a New Approach

Interleukin-10 Therapy—Review of a New Approach

Narrowband (312-nm) UV-B Suppresses Interferon γ and Interleukin (IL) 12 and Increases IL-4 Transcripts

Expression profiling of IL‐10‐regulated genes in human monocytes and peripheral blood mononuclear cells from psoriatic patients during IL‐10 therapy

Contact Info

Product

Resources

About